About Aaron Fletcher
Aaron Fletcher is a director and 10% owner at Cognition Therapeutics.
Form D filings name Aaron Fletcher as a director at Actuate Therapeutics.
Aaron Fletcher reports to the SEC as a director or major shareholder of 8 public companies, including Actuate Therapeutics (ACTU), Lantern Pharma (LTRN) and IN8BIO (INAB).
Aaron Fletcher first appears on SEC filings in 2015.
Experience
This experience comes from SEC filings. The years are when the filings name Aaron Fletcher in the role, so the role may have started earlier or lasted longer.
CI
Cognition Therapeutics Inc.
Director and 10% owner
2021 – 2026 · Public company (CGTX)
LI
Lantern Pharma Inc.
10% owner
2020 – 2025 · Public company (LTRN)
II
IN8BIO, Inc.
Director and 10% owner
2021 – 2025 · Public company (INAB)
AI
Azitra, Inc.
10% owner
2023 · Public company (AZTR)
CI
Cue Biopharma, Inc.
Director
2019 – 2023 · Public company (CUE)
TI
TFF Pharmaceuticals, Inc.
Director
2019 – 2022 · Public company (TFFP)
SC
SWK Holdings Corp
Director
2019 – 2022 · Public company (SWKH)
Key Colleagues at Startups
The people Aaron Fletcher works with at each company, as listed on that company's latest Form D.
Actuate Therapeutics, Inc. · Form D, Jul 7, 2025
TT
Todd Thomson
Director
DS
Daniel Schmitt
Executive officer and director
PL
Paul Lytle
Chief Financial Officer
RS
Roger Sawhney
Director
AM
Andrew Mazar
Executive officer
AR
Amy Ronneberg
Director
DZ
Daniel Zabrowski
Director
JK
Jason Keyes
Director